This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2012 May 4;18(5):636.

doi: 10.1038/nm0512-636a.

Biologic drugs set to top 2012 sales

No authors listed

PMID: 22561805
DOI: 10.1038/nm0512-636a

Biologic drugs set to top 2012 sales

No authors listed. Nat Med. 2012.

. 2012 May 4;18(5):636.

doi: 10.1038/nm0512-636a.

PMID: 22561805
DOI: 10.1038/nm0512-636a

No abstract available

PubMed Disclaimer

Similar articles

Tumor necrosis factor inhibitor therapy for rheumatoid arthritis.
Naguwa SM. Naguwa SM. Ann N Y Acad Sci. 2005 Jun;1051:709-15. doi: 10.1196/annals.1361.115. Ann N Y Acad Sci. 2005. PMID: 16127011 Review.
Biologic therapy for early rheumatoid arthritis: the latest evidence.
Castro-Rueda H, Kavanaugh A. Castro-Rueda H, et al. Curr Opin Rheumatol. 2008 May;20(3):314-9. doi: 10.1097/BOR.0b013e3282f5fcf6. Curr Opin Rheumatol. 2008. PMID: 18388524 Review.
Biologic therapy for rheumatoid arthritis.
Klippel JH. Klippel JH. N Engl J Med. 2000 Nov 30;343(22):1640-1. doi: 10.1056/NEJM200011303432210. N Engl J Med. 2000. PMID: 11096174 No abstract available.
Use of biologic agents in rheumatoid arthritis: introduction.
Silman AJ. Silman AJ. Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv3-4. doi: 10.1093/rheumatology/ker239. Rheumatology (Oxford). 2011. PMID: 21859703 No abstract available.
Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F, Murdaca G, Ghio M, Indiveri F. Puppo F, et al. Autoimmun Rev. 2005 Nov;4(8):537-41. doi: 10.1016/j.autrev.2005.04.016. Autoimmun Rev. 2005. PMID: 16214092 Review.

See all similar articles

Cited by

Inhibition of α-helix-mediated protein-protein interactions using designed molecules.
Azzarito V, Long K, Murphy NS, Wilson AJ. Azzarito V, et al. Nat Chem. 2013 Mar;5(3):161-73. doi: 10.1038/nchem.1568. Nat Chem. 2013. PMID: 23422557 Review.
Mapping the Pareto optimal design space for a functionally deimmunized biotherapeutic candidate.
Salvat RS, Parker AS, Choi Y, Bailey-Kellogg C, Griswold KE. Salvat RS, et al. PLoS Comput Biol. 2015 Jan 8;11(1):e1003988. doi: 10.1371/journal.pcbi.1003988. eCollection 2015 Jan. PLoS Comput Biol. 2015. PMID: 25568954 Free PMC article.
Tumor necrosis factor inhibitors - state of knowledge.
Lis K, Kuzawińska O, Bałkowiec-Iskra E. Lis K, et al. Arch Med Sci. 2014 Dec 22;10(6):1175-85. doi: 10.5114/aoms.2014.47827. Arch Med Sci. 2014. PMID: 25624856 Free PMC article.
Update on the safety and bioequivalence of biosimilars - focus on enoxaparin.
Jeske W, Walenga JM, Hoppensteadt D, Fareed J. Jeske W, et al. Drug Healthc Patient Saf. 2013 Jun 10;5:133-41. doi: 10.2147/DHPS.S28813. Print 2013. Drug Healthc Patient Saf. 2013. PMID: 23788840 Free PMC article.
Biomarkers in sepsis.
Singer M. Singer M. Curr Opin Pulm Med. 2013 May;19(3):305-9. doi: 10.1097/MCP.0b013e32835f1b49. Curr Opin Pulm Med. 2013. PMID: 23411577 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information